A New Twist on Corporate Venture Capital
Prince Ventures and AD Little are looking exclusively to 8-12 life-science companies to finance a new VC fund, Access Partners, as well as to commercialize selected research from Access' network of about 20 research institutions. The idea is to create more powerful start-ups by beginning with a corporate partnership.
You may also be interested in...
Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.